| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
L.J. Roberts Center for Alzheimer's Research (Drs. Rogers, Kirby, Hempelman, Berry, Zalinski, Cofield, Willson, and Kogan, and L. Mansukhani), Sun Health Research Institute, Sun City, AZ; the Kinsmen Laboratory for Neurological Research (Dr. McGeer), University of British Columbia, Vancouver, BC, Canada; and the Department of Psychology (Dr. Kaszniak), University of Arizona, Tucson, AZ.
In a 6-month, double-blind, placebo-controlled study, 1100 to 150 mg/d indomethacin appeared to protect mild to moderately impaired Alzheimer's disease patients from the degree of cognitive decline exhibited by a well-matched, placebo-treated group. Over a battery of cognitive tests, indomethacin patients improved 1.3% (±1.8%), whereas placebo patients declined 8.4% (±2.3%)—a significant difference (p < 0.003). Caveats include adverse reactions to indomethacin and the limited scale of the trial.
Address correspondence and reprint requests to Dr. Joseph Rogers, Sun Health Research Institute, P.O. Box 1278, Sun City, AZ 85372.
Received September 29, 1992. Accepted for publication in final form December 7, 1992.
This article has been cited by other articles:
|
|
 |
|
  J.C.S. Breitner, S. J.P.A. Haneuse, R. Walker, S. Dublin, P. K. Crane, S. L. Gray, and E. B. Larson Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort Neurology, June 2, 2009; 72(22): 1899 - 1905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 ADAPT Research Group Cognitive Function Over Time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): Results of a Randomized, Controlled Trial of Naproxen and Celecoxib Arch Neurol, July 1, 2008; 65(7): 896 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Szekely, R. C. Green, J.C.S. Breitner, T. Ostbye, A. S. Beiser, M. M. Corrada, H. H. Dodge, M. Ganguli, C. H. Kawas, L. H. Kuller, et al. No advantage of A{beta}42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies Neurology, June 10, 2008; 70(24): 2291 - 2298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Vlad, D. R. Miller, N. W. Kowall, and D. T. Felson Protective effects of NSAIDs on the development of Alzheimer disease Neurology, May 6, 2008; 70(19): 1672 - 1677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Saddichha and V. Pandey Alzheimer's and Non-Alzheimer's Dementia: A Critical Review of Pharmacological and Nonpharmacological Strategies American Journal of Alzheimer's Disease and Other Dementias, May 1, 2008; 23(2): 150 - 161. [Abstract] [PDF]
|
|
|
|
 |
|
 S.-H. Choi, R. Langenbach, and F. Bosetti Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury FASEB J, May 1, 2008; 22(5): 1491 - 1501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Szekely, J.C.S. Breitner, A. L. Fitzpatrick, T. D. Rea, B. M. Psaty, L. H. Kuller, and P. P. Zandi NSAID use and dementia risk in the Cardiovascular Health Study*: Role of APOE and NSAID type Neurology, January 1, 2008; 70(1): 17 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. Imbimbo, E. Del Giudice, D. Colavito, A. D'Arrigo, M. D. Carbonare, G. Villetti, F. Facchinetti, R. Volta, V. Pietrini, M. F. Baroc, et al. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic Acid (CHF5074), a Novel {gamma}-Secretase Modulator, Reduces Brain beta-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease without Causing Peripheral Toxicity J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 822 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Hayden, P. P. Zandi, A. S. Khachaturian, C. A. Szekely, M. Fotuhi, M. C. Norton, J. T. Tschanz, C. F. Pieper, C. Corcoran, C. G. Lyketsos, et al. Does NSAID use modify cognitive trajectories in the elderly?: The Cache County Study Neurology, July 17, 2007; 69(3): 275 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
ADAPT Research Group Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial Neurology, May 22, 2007; 68(21): 1800 - 1808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Kang, N. Cook, J. Manson, J. E Buring, and F. Grodstein Low dose aspirin and cognitive function in the women's health study cognitive cohort BMJ, May 12, 2007; 334(7601): 987 - 987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 References PsychiatryOnline CME, May 1, 2007; 2007(1): 2 - 2. [Full Text]
|
|
|
|
 |
|
 J. Padmanabhan, M. Levy, D. W. Dickson, and H. Potter Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons Brain, November 1, 2006; 129(11): 3020 - 3034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. P. Townsend and D. Pratico Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs FASEB J, October 1, 2005; 19(12): 1592 - 1601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Koenigsknecht-Talboo and G. E. Landreth Microglial Phagocytosis Induced by Fibrillar {beta}-Amyloid and IgGs Are Differentially Regulated by Proinflammatory Cytokines J. Neurosci., September 7, 2005; 25(36): 8240 - 8249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Abrous, M. Koehl, and M. Le Moal Adult Neurogenesis: From Precursors to Network and Physiology Physiol Rev, April 1, 2005; 85(2): 523 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Geerts, J. Q. Trojanowski, and V. M.-Y. Lee Drug Discovery in Neurodegenerative Diseases Sci. Aging Knowl. Environ., February 9, 2005; 2005(6): pe4 - pe4. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. L. Simmons, R. M. Botting, and T. Hla Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition Pharmacol. Rev., September 1, 2004; 56(3): 387 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. McGeer and E. McGeer Immunotherapy for Alzheimer's Disease Sci. Aging Knowl. Environ., July 7, 2004; 2004(27): pe29 - pe29. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Nagano, X. Huang, R. D. Moir, S. M. Payton, R. E. Tanzi, and A. I. Bush Peroxidase Activity of Cyclooxygenase-2 (COX-2) Cross-links {beta}-Amyloid (A{beta}) and Generates A{beta}-COX-2 Hetero-oligomers That Are Increased in Alzheimer's Disease J. Biol. Chem., April 9, 2004; 279(15): 14673 - 14678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Reines, G. A. Block, J. C. Morris, G. Liu, M. L. Nessly, C. R. Lines, B. A. Norman, and C. C. Baranak Rofecoxib: No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study Neurology, January 13, 2004; 62(1): 66 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Norfray and J. M. Provenzale Alzheimer's Disease: Neuropathologic Findings and Recent Advances in Imaging Am. J. Roentgenol., January 1, 2004; 182(1): 3 - 13. [Full Text] [PDF]
|
|
|
|
|
|
W. Qin, L. Ho, P. N. Pompl, Y. Peng, Z. Zhao, Z. Xiang, N. K. Robakis, J. Shioi, J. Suh, and G. M. Pasinetti Cyclooxygenase (COX)-2 and COX-1 Potentiate {beta}-Amyloid Peptide Generation through Mechanisms That Involve {gamma}-Secretase Activity J. Biol. Chem., December 19, 2003; 278(51): 50970 - 50977. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Monje, H. Toda, and T. D. Palmer Inflammatory Blockade Restores Adult Hippocampal Neurogenesis Science, December 5, 2003; 302(5651): 1760 - 1765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sastre, I. Dewachter, G. E. Landreth, T. M. Willson, T. Klockgether, F. van Leuven, and M. T. Heneka Nonsteroidal Anti-Inflammatory Drugs and Peroxisome Proliferator-Activated Receptor-{gamma} Agonists Modulate Immunostimulated Processing of Amyloid Precursor Protein through Regulation of {beta}-Secretase J. Neurosci., October 29, 2003; 23(30): 9796 - 9804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shibata, T. Yamada, T. Ishii, S. Kumazawa, H. Nakamura, H. Masutani, J. Yodoi, and K. Uchida Thioredoxin as a Molecular Target of Cyclopentenone Prostaglandins J. Biol. Chem., July 3, 2003; 278(28): 26046 - 26054. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. C. Salzberg-Brenhouse, E.-Y. Chen, D. F. Emerich, S. Baldwin, K. Hogeland, S. Ranelli, D. Lafreniere, B. Perdomo, L. Novak, T. Kladis, et al. Inhibitors of Cyclooxygenase-2, but Not Cyclooxygenase-1 Provide Structural and Functional Protection against Quinolinic Acid-Induced Neurodegeneration J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 218 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Aisen, K. A. Schafer, M. Grundman, E. Pfeiffer, M. Sano, K. L. Davis, M. R. Farlow, S. Jin, R. G. Thomas, and L. J. Thal Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease Progression: A Randomized Controlled Trial JAMA, June 4, 2003; 289(21): 2819 - 2826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Launer Nonsteroidal Anti-inflammatory Drugs and Alzheimer Disease: What's Next? JAMA, June 4, 2003; 289(21): 2865 - 2867. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Schwab and H. J. Schluesener Cyclooxygenases and Central Nervous System Inflammation: Conceptual Neglect of Cyclooxygenase 1 Arch Neurol, April 1, 2003; 60(4): 630 - 632. [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Clark and J. H.T. Karlawish Alzheimer Disease: Current Concepts and Emerging Diagnostic and Therapeutic Strategies Ann Intern Med, March 4, 2003; 138(5): 400 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rostagno, T. Revesz, T. Lashley, Y. Tomidokoro, L. Magnotti, H. Braendgaard, G. Plant, M. Bojsen-Moller, J. Holton, B. Frangione, et al. Complement Activation in Chromosome 13 Dementias. SIMILARITIES WITH ALZHEIMER'S DISEASE J. Biol. Chem., December 13, 2002; 277(51): 49782 - 49790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. in 't Veld, L. J. Launer, M. M. B. Breteler, A. Hofman, and B. H. Ch. Stricker Pharmacologic Agents Associated with a Preventive Effect on Alzheimer's Disease: A Review of the Epidemiologic Evidence Epidemiol. Rev., December 1, 2002; 24(2): 248 - 268. [Full Text] [PDF]
|
|
|
|
 |
|
 K. N. Prasad, W. C. Cole, and K. C. Prasad Risk Factors for Alzheimer's Disease: Role of Multiple Antioxidants, Non-Steroidal Anti-inflammatory and Cholinergic Agents Alone or in Combination in Prevention and Treatment J. Am. Coll. Nutr., December 1, 2002; 21(6): 506 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Cui, Y. Le, H. Yazawa, W. Gong, and J. M. Wang Potential role of the formyl peptide receptor-like 1 (FPRL1) in inflammatory aspects of Alzheimer's disease J. Leukoc. Biol., October 1, 2002; 72(4): 628 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. P. Zandi, J. C. Anthony, K. M. Hayden, K. Mehta, L. Mayer, and J. C.S. Breitner Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County Study Neurology, September 24, 2002; 59(6): 880 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-H. Suh and F. Checler Amyloid Precursor Protein, Presenilins, and alpha -Synuclein: Molecular Pathogenesis and Pharmacological Applications in Alzheimer's Disease Pharmacol. Rev., September 1, 2002; 54(3): 469 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Avramovich, T. Amit, and M. B. H. Youdim Non-steroidal Anti-inflammatory Drugs Stimulate Secretion of Non-amyloidogenic Precursor Protein J. Biol. Chem., August 23, 2002; 277(35): 31466 - 31473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. McGeer and E. G. McGeer Innate Immunity, Local Inflammation, and Degenerative Disease Sci. Aging Knowl. Environ., July 24, 2002; 2002(29): re3 - 3. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Chappell and H. Cohen Frontiers in Neuropharmacotherapy Part I: Alzheimer's Disease and Epilepsy Journal of Pharmacy Practice, June 1, 2002; 15(3): 195 - 220. [Abstract] [PDF]
|
|
|
|
|
|
P. S. Aisen, J. Schmeidler, and G. M. Pasinetti Randomized pilot study of nimesulide treatment in Alzheimer's disease Neurology, April 9, 2002; 58(7): 1050 - 1054. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. T. Jantzen, K. E. Connor, G. DiCarlo, G. L. Wenk, J. L. Wallace, A. M. Rojiani, D. Coppola, D. Morgan, and M. N. Gordon Microglial Activation and beta -Amyloid Deposit Reduction Caused by a Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drug in Amyloid Precursor Protein Plus Presenilin-1 Transgenic Mice J. Neurosci., March 15, 2002; 22(6): 2246 - 2254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. TEGEDER, J. PFEILSCHIFTER, and G. GEISSLINGER Cyclooxygenase-independent actions of cyclooxygenase inhibitors FASEB J, October 1, 2001; 15(12): 2057 - 2072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Doody, J.C. Stevens, C. Beck, R.M. Dubinsky, J.A. Kaye, L. Gwyther, R.C. Mohs, L.J. Thal, P.J. Whitehouse, S.T. DeKosky, et al. Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology, May 8, 2001; 56(9): 1154 - 1166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. G. McGeer and P. L. McGeer Innate Immunity in Alzheimer's Disease: A Model for Local Inflammatory Reactions Mol. Interv., April 1, 2001; 1(1): 22 - 29. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. Landi, G. Onder, C. Cattel, G. Gambassi, F. Lattanzio, M. Cesari, A. Russo, and R. Bernabei Functional Status and Clinical Correlates in Cognitively Impaired Community-Living Older People J Geriatr Psychiatry Neurol, March 1, 2001; 14(1): 21 - 27. [Abstract] [PDF]
|
|
|
|
|
|
L. Ho, D. Purohit, V. Haroutunian, J. D. Luterman, F. Willis, J. Naslund, J. D. Buxbaum, R. C. Mohs, P. S. Aisen, and G. M. Pasinetti Neuronal Cyclooxygenase 2 Expression in the Hippocampal Formation as a Function of the Clinical Progression of Alzheimer Disease Arch Neurol, March 1, 2001; 58(3): 487 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Combs, J. C. Karlo, S.-C. Kao, and G. E. Landreth {beta}-Amyloid Stimulation of Microglia and Monocytes Results in TNF{alpha}-Dependent Expression of Inducible Nitric Oxide Synthase and Neuronal Apoptosis J. Neurosci., February 15, 2001; 21(4): 1179 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Broe, D. A. Grayson, H. M. Creasey, L. M. Waite, B. J. Casey, H. P. Bennett, W. S. Brooks, and G. M. Halliday Anti-inflammatory Drugs Protect Against Alzheimer Disease at Low Doses Arch Neurol, November 1, 2000; 57(11): 1586 - 1591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. R. A. Mackenzie Activated microglia in dementia with Lewy bodies Neurology, July 12, 2000; 55(1): 132 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. McGeer and E. G. McGeer Autotoxicity and Alzheimer Disease Arch Neurol, June 1, 2000; 57(6): 789 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. I. Engelhardt, W.-D. Le, L. Siklos, I. Obal, K. Boda, and S. H. Appel Stereotaxic Injection of IgG From Patients With Alzheimer Disease Initiates Injury of Cholinergic Neurons of the Basal Forebrain Arch Neurol, May 1, 2000; 57(5): 681 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Emilien, K. Beyreuther, C. L. Masters, and J.-M. Maloteaux Prospects for Pharmacological Intervention in Alzheimer Disease Arch Neurol, April 1, 2000; 57(4): 454 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. B. Larson An 80-Year-Old Man With Memory Loss JAMA, February 23, 2000; 283(8): 1046 - 1053. [Full Text] [PDF]
|
|
|
|
|
|
P. S. Aisen, K. L. Davis, J. D. Berg, K. Schafer, K. Campbell, R. G. Thomas, M. F. Weiner, M. R. Farlow, M. Sano, M. Grundman, et al. A randomized controlled trial of prednisone in Alzheimer's disease Neurology, February 8, 2000; 54(3): 588 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Nourhashemi, S. Gillette-Guyonnet, S. Andrieu, A. Ghisolfi, P. J. Ousset, H. Grandjean, A. Grand, J. Pous, B. Vellas, and J.-L. Albarede Alzheimer disease: protective factors1 Am. J. Clinical Nutrition, February 1, 2000; 71(2): 643s - 649s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Combs, D. E. Johnson, J. C. Karlo, S. B. Cannady, and G. E. Landreth Inflammatory Mechanisms in Alzheimer's Disease: Inhibition of beta -Amyloid-Stimulated Proinflammatory Responses and Neurotoxicity by PPARgamma Agonists J. Neurosci., January 15, 2000; 20(2): 558 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Munoz and H. Feldman Causes of Alzheimer's disease Can. Med. Assoc. J., January 1, 2000; 162(1): 65 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Scharf, A. Mander, A. Ugoni, F. Vajda, and N. Christophidis A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease Neurology, July 1, 1999; 53(1): 197 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yasojima, C. Schwab, E. G. McGeer, and P. L. McGeer Up-Regulated Production and Activation of the Complement System in Alzheimer's Disease Brain Am. J. Pathol., March 1, 1999; 154(3): 927 - 936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Felician and T. A. Sandson The Neurobiology and Pharmacotherapy of Alzheimer's Disease J Neuropsychiatry Clin Neurosci, February 1, 1999; 11(1): 19 - 31. [Abstract] [Full Text]
|
|
|
|
|
|
D. S. Knopman and J. C. Morris An Update on Primary Drug Therapies for Alzheimer Disease Arch Neurol, November 1, 1997; 54(11): 1406 - 1409. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Uchihara, H. Akiyama, H. Kondo, and K. Ikeda Activated Microglial Cells Are Colocalized With Perivascular Deposits of Amyloid-{beta} Protein in Alzheimer's Disease Brain Stroke, October 1, 1997; 28(10): 1948 - 1950. [Abstract] [Full Text]
|
|
|
|
|
|
R. M. Keimowitz Dementia Improvement With Cytotoxic Chemotherapy: A Case of Alzheimer Disease and Multiple Myeloma Arch Neurol, April 1, 1997; 54(4): 485 - 488. [Abstract] [PDF]
|
|
|
|
 |
|
 N.H.P. Allen and A. Burns The treatment of Alzheimer's disease J Psychopharmacol, January 1, 1995; 9(1): 43 - 56. [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
